Hal V. Barron
E295849
Hal V. Barron is a prominent physician-scientist and biopharmaceutical executive known for leading research and development at major companies and for his work in aging and longevity-focused biotechnology.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Hal V. Barron canonical | 1 |
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical executive
ⓘ
businessperson ⓘ physician-scientist ⓘ research and development leader ⓘ |
| boardMemberOf | Altos Labs ⓘ |
| countryOfCitizenship | United States of America ⓘ |
| educatedAt |
Yale School of Medicine
ⓘ
Yale University ⓘ |
| employer |
Altos Labs
ⓘ
Calico Life Sciences ⓘ Genentech ⓘ GlaxoSmithKline ⓘ Roche ⓘ |
| fieldOfWork |
aging research
ⓘ
biotechnology ⓘ cardiology ⓘ drug development ⓘ longevity biotechnology ⓘ medicine ⓘ |
| hasAcademicDegree |
Bachelor’s degree
ⓘ
Doctor of Medicine ⓘ |
| hasGender | male ⓘ |
| hasNotableAchievement |
helped shape R&D strategy at multiple global pharmaceutical companies
ⓘ
pioneered corporate efforts focused on human longevity and aging biology ⓘ |
| hasRole | leader of multidisciplinary R&D organizations ⓘ |
| industry |
biotechnology industry
ⓘ
pharmaceutical industry ⓘ |
| knownFor |
leadership in pharmaceutical research and development
ⓘ
work in aging and longevity-focused biotechnology ⓘ |
| notableFor | senior leadership roles at Genentech, Roche, GSK, Calico, and Altos Labs ⓘ |
| notableWork |
development of therapies targeting aging-related diseases
ⓘ
oversight of large pharmaceutical R&D portfolios ⓘ |
| occupation |
corporate executive
ⓘ
physician ⓘ scientist ⓘ |
| positionHeld |
Chief Executive Officer of Altos Labs
ⓘ
Chief Medical Officer of Genentech ⓘ Chief Scientific Officer of GlaxoSmithKline ⓘ Co‑Chair of the Board of Directors of Altos Labs ⓘ Head of Global Product Development at Roche ⓘ President of Research and Development at Calico Life Sciences ⓘ President of Research and Development at GlaxoSmithKline ⓘ |
| researchInterest |
aging biology
ⓘ
cardiovascular disease ⓘ oncology ⓘ regenerative medicine ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.